Vestal Point Capital portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Vestal Point Capital reported a $4.3 bn portfolio of 68 positions to the SEC as of the end of Q2 2026. Its largest positions are BMRN, NBIX, ABVX. During the quarter it opened Abbott Laboratories and exited Apogee Therapeutics and Scholar Rock Holding.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Vestal Point Capital has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
What changed this quarter
86 positions with a change (7 new, 30 added to, 21 trimmed, 28 sold); also, 1 entered through an IPO, 3 exited through an acquisition or merger, 1 entered through a spin-off. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Revolution Medicines−81%fewer sharesReduced6.5% → 2.0%
- United Therapeutics+480%more sharesIncreased1.2% → 5.5%
- BioMarin Pharmaceutical+69%more sharesIncreased5.6% → 8.1%
- Abbott Laboratories+3.0 ppof portfolioNew— → 3.0%
- Abivax+57%more sharesIncreased4.7% → 7.3%
- Neurocrine Biosciences+50%more sharesIncreased4.6% → 7.4%
- Zimmer Biomet Holdings+637%more sharesIncreased0.5% → 2.8%
- Insulet+1,224%more sharesIncreased0.3% → 2.4%
- Apogee Therapeutics−2.2 ppof portfolioSold out2.6% → —
- Repligen−57%fewer sharesReduced3.0% → 1.3%
- Astrazeneca+350%more sharesIncreased0.6% → 2.0%
- Scholar Rock Holding−1.5 ppof portfolioSold out1.8% → —
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- BioMarin PharmaceuticalBMRN8.1%
- Neurocrine BiosciencesNBIX7.4%
- AbivaxABVX7.3%
- United TherapeuticsUTHR5.5%
- Enliven TherapeuticsELVN4.7%
- Nurix TherapeuticsNRIX4.6%
- Bicara TherapeuticsBCAX3.6%
- Taysha Gene TherapiesTSHA3.1%
- Arrowhead PharmaceuticalsARWR3.0%
- Abbott LaboratoriesABT3.0%
- Zimmer Biomet HoldingsZBH2.8%
- Disc MedicineIRON2.6%
- Monte Rosa TherapeuticsGLUE2.6%
- InsuletPODD2.4%
- Ascendis Pharma A/SASND2.3%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 68
Q2 2026: 50%
Q2 2026: 31.4%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 31, 2026 (high confidence).
The data, as reported: VESTAL POINT CAPITAL, LP (CRD 325894): 7.B private funds: 1 hedge (gross assets $2.8 bn); 5.D assets by client type: pooled vehicles 51%, other 49% (of $5.5 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Hill City CapitalInvestment firm · $4.3 bn
- AKO Capital LLPInvestment firm · $4.3 bn
- Marshfield AssociatesInvestment firm · $4.3 bn
- Altarock PartnersInvestment firm · $4.2 bn
- Trian Fund ManagementInvestment firm · $4.2 bn
- Contour Asset ManagementInvestment firm · $4.2 bn